ClinicalTrials.gg
RecruitingNCT05242861RetroBTUpdated Feb 16, 2022

Retrospective Study of Brachytherapy

An observational study in Brachytherapy, Uterine Cervical Neoplasms and Uterine Neoplasms, sponsored by Zhejiang Cancer Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-02-16.

Sponsored by Zhejiang Cancer Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
300
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Uterine Cervical Neoplasms by Zhejiang Cancer Hospital — 5 open to participants now, 5 under way, 1 of them phase 3. Uterine Cervical Neoplasms · Zhejiang Cancer Hospital.

Started
2022
with 2 others
Observational
2 of 10
2 open now
Registered
6th of 10
by date

Among the 10 studies in Uterine Cervical Neoplasms by Zhejiang Cancer Hospital, this one is one of 3 that started in 2022, is one of 2 observational ones, and was the 6th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

5 of the 10 studies in Uterine Cervical Neoplasms by Zhejiang Cancer Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Uterine Cervical Neoplasms by Zhejiang Cancer Hospital, or all of them as a file.
02

Study summary

Brachytherapy for gynecological cancers will be studied retrospectively.

03

Conditions studied

  • Brachytherapy
  • Uterine Cervical Neoplasms
  • Uterine Neoplasms
  • Vulvar Cancer
  • Vaginal Cancer
  • Ovarian Neoplasms
  • Gynecologic Neoplasm

Keywords

  • Brachytherapy
  • Cervical Cancer
  • Endometrial Cancer
  • Vaginal Cancer
  • Vulvar Cancer
  • Image Guided
  • 3D Print
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

18 to 80 years old female who diagnosed as gynecological cancer and underwent brachytherapy will be enrolled in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 - 80 female
  • Underwent brachytherapy
  • With gynecological cancer

Exclusion criteria

Exclusion Criteria:

  • Refusal to enter this trial
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cervix radical BT

    Radiation: Brachytherapy

  • Cervix adjuvant BT

    Radiation: Brachytherapy

  • Cervix palliative BT

    Radiation: Brachytherapy

  • Uterus BT

    Radiation: Brachytherapy

  • Other GO cancer BT

    Radiation: Brachytherapy

Interventions

  • RadiationBrachytherapy

    Applicator, dose, schedule, technology, image, 3D print, efficacy, toxicity of brachytherapy

06

What researchers measure

Primary outcomes

  1. Overall survival rate

    the percentage of participants in the group who survives

    Time frame: 5-year

Secondary outcomes

  1. Progression-free survival rate

    the percentage of participants in the group whose disease is likely to remain stable

    Time frame: 5-year

  2. Side effects

    side effects associated with treatment

    Time frame: 5-year

07

Study locations

1 of 1 sites recruiting
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
    Recruiting
    • Xiang Zhang · Contactzhangxiang@zjcc.org.cn · 0086-571-88122048
    • Xiang Zhang · Principal investigator
    • Jianhong Chen · Sub investigator
    • Yeqiang Tu · Sub investigator
08

References and documents

Publications

  • Sturdza A, Potter R, Fokdal LU, Haie-Meder C, Tan LT, Mazeron R, Petric P, Segedin B, Jurgenliemk-Schulz IM, Nomden C, Gillham C, McArdle O, Van Limbergen E, Janssen H, Hoskin P, Lowe G, Tharavichitkul E, Villafranca E, Mahantshetty U, Georg P, Kirchheiner K, Kirisits C, Tanderup K, Lindegaard JC. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol. 2016 Sep;120(3):428-433. doi: 10.1016/j.radonc.2016.03.011. Epub 2016 Apr 29. PubMed 27134181 ↗
  • Lindegaard JC, Madsen ML, Traberg A, Meisner B, Nielsen SK, Tanderup K, Spejlborg H, Fokdal LU, Norrevang O. Individualised 3D printed vaginal template for MRI guided brachytherapy in locally advanced cervical cancer. Radiother Oncol. 2016 Jan;118(1):173-5. doi: 10.1016/j.radonc.2015.12.012. Epub 2015 Dec 29. PubMed 26743833 ↗
  • Sekii S, Tsujino K, Kosaka K, Yamaguchi S, Kubota H, Matsumoto Y, Ota Y, Sasaki R, Soejima T. Inversely designed, 3D-printed personalized template-guided interstitial brachytherapy for vaginal tumors. J Contemp Brachytherapy. 2018 Oct;10(5):470-477. doi: 10.5114/jcb.2018.78832. Epub 2018 Oct 9. PubMed 30479625 ↗
  • Harris BD, Nilsson S, Poole CM. A feasibility study for using ABS plastic and a low-cost 3D printer for patient-specific brachytherapy mould design. Australas Phys Eng Sci Med. 2015 Sep;38(3):399-412. doi: 10.1007/s13246-015-0356-3. Epub 2015 Jun 25. PubMed 26108891 ↗
  • Han K, Milosevic M, Fyles A, Pintilie M, Viswanathan AN. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):111-9. doi: 10.1016/j.ijrobp.2013.05.033. Epub 2013 Jul 9. PubMed 23849695 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2022; primary completion for Dec 2024, 34 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2022
First posted
Feb 16, 2022
StartEst.
Feb 20, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2027
Last update
Feb 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05242861
Responsible party
Sponsor
First posted
Feb 16, 2022
Start date
Feb 20, 2022 (estimated)
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 16, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion